Welcome to our dedicated page for Kymera Therapeutics news (Ticker: KYMR), a resource for investors and traders seeking the latest updates and insights on Kymera Therapeutics stock.
Kymera Therapeutics develops targeted protein degradation medicines for immunological diseases as a clinical-stage biopharmaceutical company. News about KYMR commonly centers on oral small molecule degrader programs, including KT-621, a STAT6 degrader for Type 2 inflammatory diseases such as atopic dermatitis and asthma, and KT-579, an IRF5 degrader tied to inflammatory bowel disease biology.
Company updates also cover preclinical and clinical data presentations, FDA regulatory designations, collaboration activity involving degrader candidates such as KT-200, and periodic operating and financial results. Additional announcements include investor conference participation and shareholder voting matters.
Kymera Therapeutics (NASDAQ: KYMR) will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on June 3, 2026 at 8:10 a.m. ET.
A live webcast and archived replay will be available in the Investors “News and Events” section of the company website.
Kymera Therapeutics (NASDAQ: KYMR) reported new Phase 1b data for KT-621, a first-in-class, oral STAT6 degrader, in atopic dermatitis. Presentations at the Society for Investigative Dermatology and American Thoracic Society highlight robust STAT6 degradation in skin and blood, biomarker reductions, and associated clinical efficacy measures.
Parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, are ongoing with data expected by mid-2027 and late 2027, respectively, to support potential later Phase 3 development across Type 2 inflammatory diseases.
Kymera Therapeutics (NASDAQ: KYMR) will present at two investor conferences in May 2026 via fireside chats: Bank of America Healthcare Conference in Las Vegas on May 12, 2026 at 9:20 a.m. PT and RBC Capital Markets Global Healthcare Conference in New York on May 19, 2026 at 9:00 a.m. ET.
According to the company, live webcasts and archived replays will be available in the Investors > News and Events section at www.kymeratx.com.
Kymera Therapeutics (NASDAQ: KYMR) presented preclinical data for KT-579, an oral IRF5 degrader, at Digestive Disease Week on May 5, 2026. KT-579 reduced disease activity in a TNBS IBD model, fully inhibited key colon cytokines (TNFα, IL-1β, IL-6), and normalized inflammatory and fibrosis-related transcripts.
The Phase 1 healthy volunteer study is ongoing; the company expects to report human data in the second half of 2026.
Jeito Capital (BIIB) announced the appointments of Elaine Caughey, MBA as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA as Partner, Talent, effective May 5, 2026. Both bring 20+–30+ years of life‑sciences experience across investment funds, pharma and biopharma.
Elaine will support BD, partnerships, acquisitions and U.S. expansion; Sarah will lead senior hiring, board building and talent strategy across the portfolio. The hires complement recent senior additions to strengthen Jeito’s operating and regulatory capabilities.
Kymera Therapeutics (NASDAQ: KYMR) reported Q1 2026 results and pipeline updates. Key highlights: $1.55 billion cash runway into 2029; $34.4M collaboration revenue; Q1 net loss $69.2M. Gilead exercised option on KT-200, triggering a $45M milestone. KT-621 Phase 2b trials (BROADEN2 in AD, BREADTH in asthma) ongoing with data expected mid-2027 and late 2027; FDA granted Fast Track for KT-621 in eosinophilic asthma. KT-579 Phase 1 data expected 2H26. Company to webcast investor call today at 8:30 a.m. ET.
Kymera Therapeutics (NASDAQ: KYMR) will report first quarter 2026 financial results on April 30, 2026. The company will host a video conference call and webcast at 8:30 a.m. ET that day. Registration and a replay will be available via the Investors section at www.kymeratx.com.
Kymera Therapeutics (NASDAQ: KYMR) announced U.S. FDA Fast Track designation for KT-621, a first-in-class oral STAT6 degrader for moderate to severe eosinophilic asthma.
KT-621 is in global Phase 2b trials for asthma and atopic dermatitis, with asthma data expected in late 2027 and AD data by mid-2027.
Kymera (NASDAQ: KYMR) announced Gilead Sciences exercised its option to exclusively license KT-200, an oral CDK2 molecular glue degrader, triggering a $45 million milestone payment. Gilead will advance KT-200 into IND-enabling studies aiming for an IND filing in 2027. Kymera remains eligible for up to $750 million in total payments and tiered royalties.
Preclinical data cited low-nanomolar CDK2 degradation, activity in CCNE1-amplified models, brain-penetrant potential, and a favorable safety profile.
Kymera Therapeutics (NASDAQ: KYMR) reported positive Phase 1b BroADen results for oral STAT6 degrader KT-621, presented at AAD 2026. In 22 moderate-to-severe atopic dermatitis patients, 28-day dosing produced median STAT6 degradation up to 98% in blood and meaningful reductions in clinical and biomarker endpoints.
Parallel Phase 2b trials in atopic dermatitis (BROADEN2) and asthma (BREADTH) are ongoing, with data expected by mid-2027 and late-2027, respectively.